Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming.

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Synovial sarcoma (SyS) is an aggressive soft-tissue cancer driven by the SS18::SSX fusion oncoprotein.
• The SS18::SSX fusion is thought to deregulate chromatin architecture, driving oncogenesis.

Approach:

• Comprehensive multi-omics analysis was performed on 52 primary, pre-treatment human SyS tumors.
• Investigated epigenomic states, enhancer signatures, and histone modifications.
• Analyzed the prognostic value of bivalent promoters and DNA methylation patterns.

Key Points:

• A continuum of epigenomic states was observed across SyS tumors, independent of genetic mutations.
• Cell-of-origin signatures were identified through enhancer states.
• Bivalent promoters (H3K27me3/H3K4me3) demonstrated strong prognostic value, outperforming tumor grade.
• SyS exhibits unique epigenomic features, including H3K4me3 expansion and significant promoter hypomethylation.

Conclusions:

• Epigenomic profiling provides insights into SyS biology and identifies potential therapeutic vulnerabilities.
• H3K4me3 inhibition is a promising therapeutic strategy for synovial sarcoma.